N-末端脑钠肽前体在AECOPD合并肺心病诊治中的价值

Clinical value of NT-ProBNP in AECOPD patients complicated with cor pulmonale

目的探讨血清N-末端脑钠肽前体(NT-ProBNP)水平对慢性阻塞性肺疾病急性加重期(AECOPD)合并肺心病的临床价值。方法 66例AECOPD患者分为两组:AECOPD合并肺心病组30例,AECOPD组36例,测定两组患者血清NT-ProBNP水平及动脉血气分析(PaO2、PaCO2)进行比较,并将AECOPD合并肺心病组患者治疗前后血清NT-ProBNP水平及动脉血气分析(PaO2、PaCO2)进行比较。结果 AECOPD合并肺心病组患者血清NT-ProBNP、PaCO2水平明显高于AECOPD组(P<0.01),PaO2明显低于AECOPD组(P<0.01)。AECOPD合并肺心病组患者治疗后血清NT-ProBNP、PaCO2水平明显低于治疗前(P<0.01),PaO2明显高于治疗前(P<0.01)。结论血清NT-ProBNP有助于判断AECOPD患者是否合并肺心病及评估治疗效果。

Objective To evaluate the clinical value of serum NT-ProBNP in AECOPD patients complicated with eor pulmonale. Methods 66 patients with AECOPD were divided into two groups ： the study group of AECOPD complicated with cor pulmonale （30 cases） and the control group of AECOPD （36 cases）. The differences of serum NT-ProBNP level and blood gas analysis were detected between the two groups. Results The levels of serum NT- ProBNP and PaCOz were significantly higher in the study group than in the control group （P 〈 0. 01 ）, and the level of PaO2 was significantly lower inaobviously the study group than in the control group （P 〈 0. 01 ）. After the treatment, the levels of serum NT-ProBNP and PaCO2 decreased obviously （P 〈0. 01 ）, and the level of PaO： increased （ P 〈 0. 01 ）. Conclusion Serum NT-ProBNP contributes to decide whether the AECOPD patients are associated with cor pulmonale or not, as well as to evaluate treatment effectiveness.